EVENTS

Stock Quote

Stock Quote: TSE

Price 0.24

Change +0.00

Volume 8,000

% Change +0%

Intraday High 0.25

52 Week High 0.52

Intraday Low 0.24

52 Week Low 0.11

Today's Open 0.24

Previous Close 0.24

Oct 12, 2018 03:39 PM Pricing delayed 20 minutes

Analyst Coverage

Name Institution Phone Number
André Uddin Mackie Research Capital (416) 860-8675

Acerus Pharmaceuticals Corporation is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Acerus Pharmaceuticals Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Acerus Pharmaceutical Corporation or its management. Acerus Pharmaceuticals Corporation does not, in any event but including, without limitation, by its reference above or distribution, imply its endorsement of or concurrence with such information, conclusions or recommendations.

FAQ

When was Acerus founded and when did it become a public company?

Acerus was incorporated under the Business Corporations Act (Ontario) on July 15, 2009 as J5 Acquisition Corp. (“J5”). From incorporation until July 11, 2011, when J5 amended its articles of incorporation to change its name to “Trimel Pharmaceuticals Corporation”, the Corporation operated as a “capital pool company” (“CPC”) pursuant to Policy 2.4 of the TSX Venture Exchange (“TSX-V”) Corporate Finance Manual. On July 14, 2011, J5 (Barbados), Inc., a wholly-owned subsidiary of J5 incorporated under Barbados law, amalgamated with Trimel BioPharma Holdings Inc. (“Trimel Holdings”) under the name “Trimel BioPharma Holdings Inc.” Upon completion of the amalgamation, the Corporation completed its qualifying transaction (“the Qualifying Transaction”) by way of a reverse takeover transaction through an exchange of shares, resulting in the former shareholders of Trimel Holdings obtaining control of the Corporation and acquiring 100% of the common shares of the Corporation. On September 8, 2015, the name of the Corporation was formally changed from “Trimel Pharmaceuticals Corporation” to “Acerus Pharmaceuticals Corporation”.

On July 19, 2011, the Corporation’s common shares were delisted from the TSX-V and graduated and listed for trading on the Toronto Stock Exchange (the “TSX”) under the symbol “TRL”. Concurrent with the change of corporate name in September 2015, the trading symbol of the Acerus Common Shares on the TSX was changed to “ASP”.

back to top

What is Acerus’ ticker? What exchange does it trade on?

Acerus trades on the Toronto Stock Exchange under the ticker “ASP”.

back to top

What is Acerus’ year-end?

Acerus’ year-end is December 31.

back to top

What currency does Acerus report in?

Acerus is currently reporting in U.S. Dollars.

back to top

Who is Acerus’ current auditor?

Acerus’ current auditor is PricewaterhouseCoopers LLP.

back to top

Where can I get access to Acerus’ regulatory and financial filings?

These filings are available on this page above and on the SEDAR website at www.sedar.com.

back to top

Does Acerus pay a dividend?

The declaration and payment of dividends on the Acerus Common Shares is at the discretion of the Corporation’s board of directors. It is the board of directors’ present policy to retain its earnings to finance growth, fund future development projects and expand its operations. As such, it does not anticipate paying any dividends in the foreseeable future.

back to top

Can I buy shares directly from Acerus?

There is no mechanism to purchase shares directly from Acerus.

back to top

Who do I contact if I have general questions about my shareholdings?

Investors are invited to contact the Company’s Transfer Agent, TSX Trust Company, with general questions about their shareholdings, including the loss of share certificates or a change of address.

TSX Trust Company can be reached using the following methods:
Phone: +1 (416) 342-1091 or toll free on 1 866 600 5869
E-mail: tmxeinvestorservices@tmx.com

Mail:

Attn: Investor Services
301 – 100 Adelaide Street West
Toronto, Ontario
M5H 4H1

back to top

Email Alerts

To receive press release notifications via email, fill out the form below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription.

*Required fields

Unsubscribe

By entering your email address below, you will no longer receive email alerts. If you do unsubscribe from email alerts, you can subscribe again at any time by using the sign up process above.

Email Address: *